Loading
A radioactive drug for neuroendocrine tumours: a small peptide that homes to the somatostatin receptor on the tumour cells carries lutetium-177, which irradiates them from within. Given four times, two months apart.
Neuroendocrine tumours overexpress somatostatin receptor 2, imaged with gallium-68 or copper-64 DOTATATE PET and treated first with cold somatostatin analogues (octreotide, lanreotide) for symptom and growth control. 177Lu-DOTATATE (NETTER-1, approved 2018) improved progression-free survival dramatically in midgut NETs and NETTER-2 (2024) moved it to first line in high-grade tumours; 177Lu-edotreotide (COMPETE) followed. Alpha-emitting versions (212Pb-DOTAMTATE, 225Ac-DOTATATE) are in phase 3 for PRRT-refractory disease. Toxicities are marrow suppression, kidney dose and a small risk of MDS. Together with radioiodine and PSMA therapy it defines the theranostic model.
In plain words · Somatostatin receptor 2 is a hormone receptor densely present on neuroendocrine tumours, and was the first theranostic target to reach routine care.
Showing the target this term concerns: Somatostatin receptor 2.
The glossary entry explains the word; the readout page carries the scoring rule, the thresholds approvals use, the companion diagnostics and the tests.
Shares Somatostatin analogues (octreotide, lanreotide), Peptide receptor radionuclide therapy (PRRT), Somatostatin receptor 2, Lutetium-177 dotatate.
Shares Dosimetry, Grade 3 well-differentiated neuroendocrine tumour, Theranostics, Somatostatin receptor 2.
Shares Grade 3 well-differentiated neuroendocrine tumour, Lutetium-177 dotatate, Small intestinal neuroendocrine tumours, Pancreatic neuroendocrine tumours.
Shares Grade 3 well-differentiated neuroendocrine tumour, Peptide receptor radionuclide therapy (PRRT), Somatostatin receptor 2, Small intestinal neuroendocrine tumours.
Shares Gallium-68 DOTATATE (and Cu-64 DOTATATE), Grade 3 well-differentiated neuroendocrine tumour, Theranostics, Peptide receptor radionuclide therapy (PRRT).
Shares Theranostics, Peptide receptor radionuclide therapy (PRRT), Somatostatin receptor 2, Lutetium-177 dotatate.
Shares Alpha vs beta emitters, Dosimetry, Somatostatin receptor 2, Targeted alpha therapy.
Shares Dosimetry, Grade 3 well-differentiated neuroendocrine tumour, Peptide receptor radionuclide therapy (PRRT), Lutetium-177 dotatate.